Bio-Techne Aktie
| 75,12USD | -0,92USD | -1,21% |
WKN DE: A12ENG / ISIN: US09073M1045
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98,95 |
| The Vanguard Group, Inc. | 11,49 |
| Vanguard Group, Inc. (Subfiler) | 11,11 |
| T. Rowe Price Associates, Inc. (IM) | 5,94 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 5,80 |
| State Street Corp. | 4,03 |
| T Rowe Price New Horizons Fund | 3,68 |
| BlackRock Fund Advisors | 3,46 |
| Vanguard Total Stock Market ETF | 3,17 |
| BAMCO, Inc. | 2,80 |
| Vanguard 500 Index Fund | 2,63 |
| Vanguard Small Cap Index Fund | 2,51 |
| Geode Capital Management LLC | 2,46 |
| BlackRock Institutional Trust Co. NA | 2,37 |
| LB Hercules Holdings LLC | 2,22 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 2 300 | 2 600 | 3 000 | 3 050 | 3 100 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,32 | 0,36 | 0,37 | 0,37 | 0,37 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 521 | 511 | 606 | 621 | 617 |
| Summe Anlagevermögen | 1 580 | 1 839 | 1 765 | 2 112 | 2 196 |
| Summe Aktiva | 2 101 | 2 350 | 2 371 | 2 734 | 2 813 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 434 | 421 | 326 | 455 | 420 |
| Summe Fremdkapital | 720 | 779 | 670 | 767 | 744 |
| Summe Eigenkapital | 1 381 | 1 571 | 1 701 | 1 967 | 2 069 |
| Summe Passiva | 2 101 | 2 350 | 2 371 | 2 734 | 2 813 |
Adresse
| 614 McKinley Place NE, 55413-2610 Minneapolis | |
| Telefon | +1 (612) 379-8854 |
| Fax | +1 (612) 656-4400 |
| Internet | http://www.bio-techne.com |
Management
|
Alpna H. Seth
Independent Director |
|
David Clair
VP-Investor Relations & Corporate Development |
|
Gary Latham
Chief Technology Officer & Vice President |
|
James T. Hippel
Chief Financial Officer & Executive Vice President |
|
John L. Higgins
Independent Director |
|
Joseph D. Keegan
Independent Director |
|
Judith Klimovsky
Independent Director |
|
Julie L. Bushman
Independent Director |
|
Kim Kelderman
President, Chief Executive Officer & Director |
|
Martin Wirtz
Senior VP-Strategy & Corporate Development |
|
Matthew F. McManus
President-Diagnostics & Genomics Segment |
|
Qi Cheng
Vice President-Quality & Regulatory |
|
Robert V. Baumgartner
Chairman |
|
Roeland Nusse
Independent Director |
|
Rupert J. Vessey
Independent Director |
|
Shane V. Bohnen
Secretary, Senior Vice President & General Counsel |
|
William A. Geist
President-Protein Sciences Segment |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
